The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Polaris Group’s lead product candidate, ADI-PEG 20 receives US and EU orphan designations

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Polaris Group’s lead product candidate, ADI-PEG 20 (pegylated arginine deiminase), received orphan drug designations for the treatment of malignant pleural mesothelioma in the U.S. and the European Union.

Having completed a successful randomized phase II trial in argininosuccinate synthetase -deficient MPM patients with ADI-PEG 20 as monotherapy, Polaris is currently conducting a phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin, the approved first-line treatment for MPM, for the treatment of MPM and non-squamous non-small cell lung carcinoma.

Polaris is also conducting clinical trials on ADI-PEG 20 both as monotherapy and in combination with other agents, for the treatment of several other indications including breast cancer, melanomas, ovarian cancer and hepatocellular carcinoma.

ADI-PEG 20 is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Sponsored

Meeting the moment: ASCO GI Cancers Symposium delivers insights and collaboration

When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.
By The American Society of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account